Sab Capra LLC
Advertisement
Sab Capra LLC, based in Logan, UT, is dedicated to developing SAB142, a disease-modifying immunotherapy aimed at delaying the onset and progression of Type 1 Diabetes (T1D). Their innovative approach seeks to change the lives of individuals affected by T1D by addressing the underlying causes of the disease rather than merely managing its symptoms.
Recognizing the multifaceted challenges of living with T1D, Sab Capra LLC focuses on preserving beta cell function over time through their lead asset, SAB142. This treatment option aims to mitigate the overactive immune response that leads to the destruction of insulin-producing beta cells in the pancreas, offering hope for improved patient outcomes.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.
Advertisement